ClinicalTrials.gg
CompletedNCT03832998OASIS(CM)Updated Oct 28, 2026Results posted

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

A Phase 3 interventional study of Erenumab Dose 1 and Erenumab Dose 2 in Migraine, sponsored by Amgen. Completed at 101 sites in 13 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

How we know

Updated Oct 28, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies testing erenumab in Migraine Disorders — 3 open to participants now, 4 under way, 1 of them phase 3. erenumab · Migraine Disorders.

Enrollment
18th of 37
284 · median 261
Started
2019
with 12 others
Phase 3
9 of 37
none open now
Registered
16th of 37
by date
Lead sponsor
20 of 37
Amgen

Among the 37 studies testing erenumab in Migraine Disorders, this one is the 18th largest by enrollment, is one of 13 that started in 2019, is one of 9 in phase 3, and was the 16th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

3 of the 37 studies testing erenumab in Migraine Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About erenumab

erenumab: first FDA approval 2018 (AIMOVIG), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing erenumab in Migraine Disorders, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with chronic migraine. The study hypothesis is that in pediatric participants with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).

Read the detailed description

This study is a phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with chronic migraine. The trial consists of four phases: screening (up to 3 weeks of initial screening and a 4-week prospective baseline phase); the DBTP (24 weeks for Group 1 subjects; 12-weeks for Group 2 subjects) in which participants receive placebo or erenumab dose 1, dose 2 or dose 3 (based on participant's body-weight) via subcutaneous injection once a month; the optional dose level blinded extension phase (40 weeks), in which all participants are assigned to receive dose 1, dose 2 or dose 3 of erenumab; and a 12 weeks safety follow-up phase (16 weeks after the last dose of investigational drug). The study intends to enrol 286 participants (256 adolescents and 30 children).

03

Conditions studied

  • Migraine

Keywords

  • Migraine
  • Headache
  • Prevention
  • Pediatric
  • Chronic Migraine
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Children (6 to less than 12 years of age) or adolescent (12 to less than 18 years of age) at the time of signing, if developmentally appropriate, the formal assent to participate to the study.
  • Participant's parent or legal representative has provided written before initiation of any study-specific activities/procedures.
  • History of migraine (with or without aura) for ≥ 12 months before screening according to the IHS Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2013) ICHD-3 specifications for pediatric migraine (participants aged less than 18 years), should be considered for the diagnosis of migraine.
  • History of ≥ 15 headache days per month of which ≥ 8 headache days were assessed by the participant as migraine days per month in each of the 3 months prior to screening.
  • Migraine frequency: greater than or equal to 8 migraine days based on the eDiary data during the last 28 days of the baseline phase if more than 28 days in duration.
  • Headache frequency of greater than or equal to 15 headache days based on the eDiary data during the last 28 days of the baseline phase if more than 28 days in duration.
  • Demonstrated at least 80% compliance with the eDiary based on the last 28 days of the baseline period, if more than 28 days in duration (eg, completing eDiary items for at least 23 out of the last 28 days of the baseline phase).

Key Exclusion Criteria:

  • History of cluster headache or hemiplegic migraine headache.
  • Chronic migraine with continuous pain, in which the participant does not have any pain free periods (of any duration) during the 1 month prior to screening.
  • No therapeutic response with greater than 3 medication categories for prophylactic treatment of migraine after an adequate therapeutic trial. No therapeutic response is defined as no reduction in headache frequency, duration, or severity after administration of the medication for at least 6 weeks at the generally-accepted therapeutic dose(s) based on the investigator's assessment.
  • History of suicidal behavior or the participant is at risk of self-harm or harm to others.
  • History of major psychiatric disorder. Participants with anxiety disorder and/or mild major depressive disorder (Patient Health Questionnaire Modified for Adolescents [PHQ-A] score 9 for adolescents or based on medical judgement of the investigator for children) are permitted in the study if they are considered by the investigator to be stable and are taking no more than 1 medication for each disorder. Participants must have been on a stable dose within the 3 months before the start of the baseline phase.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
284 participants (actual)

Study arms

  • Experimental
    Dose Level 1

    Participants will be randomized to one of two doses determined by their body weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.

    Drug: Erenumab Dose 1 · Drug: Erenumab Dose 2

  • Experimental
    Dose Level 2

    Participants will be randomized to one of two doses determined by their body-weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.

    Drug: Erenumab Dose 2 · Drug: Erenumab Dose 3

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugErenumabStudies of ErenumabErenumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.

    Also known as: AMG 334, Aimovig®

  • DrugErenumabStudies of ErenumabErenumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and participants in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.

    Also known as: AMG 334, Aimovig®

  • DrugErenumabStudies of ErenumabErenumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.

    Also known as: AMG 334, Aimovig®

  • OtherPlacebo

    Placebo matching dose for erenumab dose 1, 2 and 3.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in MMD to Week 9 Through Week 12 (Month 3) of the DBTP

    A migraine day was defined as any calendar day in which the participant developed a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). MMD was defined as the number of migraine days between each monthly IP dose. MMD at baseline was the number of migraine days in the 4-week baseline phase. The least squares mean (LSM) was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment group with scheduled visit. Participants were used as a random effect. As pre-specified in the Statistical Analysis Plan (SAP), only results from adolescents are presented.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change From Baseline in Monthly Headache Days to Week 9 Through Week 12 (Month 3) of the DBTP

    A headache day was defined as any calendar day in which the participant develops a qualified headache (onset, continuation, or recurrence of the headache). Monthly headache days were defined as the number of headache days between each monthly IP dose. Monthly headache days at baseline was the number of headache days in the 4-week baseline phase. LSM was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment with scheduled visit. Participants were used as a random effect. As pre-specified in the SAP, only results from adolescents are presented.

    Time frame: Baseline to Week 12

  2. Number of Participants With at Least 50% Reduction in MMD From Baseline to Week 9 Through Week 12 (Month 3) of the DBTP

    A migraine day was defined as any calendar day in which the participant developed a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). MMD was defined as the number of migraine days between each monthly IP dose. MMD at baseline was the number of migraine days in the 4-week baseline phase. All participants included in the overall number of participants analyzed contributed to the post-baseline data for this endpoint. As pre-specified in the SAP, only results from adolescents are presented.

    Time frame: Baseline to Week 12

  3. Change From Baseline in MMD to the Average of the First 3 Months (Week 1 Through Week 12) of the DBTP

    A migraine day was defined as any calendar day in which the participant developed a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). MMD was defined as the number of migraine days between each monthly IP dose. MMD at baseline was the number of migraine days in the 4-week baseline phase. LSM was calculated using a fixed effects analysis of covariance (ANCOVA) model, including terms for treatment group, baseline value as covariate, and stratification factors of region and prior preventive treatment failure. As pre-specified in the SAP, only results from adolescents are presented.

    Time frame: Baseline to Week 12

  4. Change From Baseline in Monthly Average Severity of Migraine Attacks to Week 9 Through Week 12 (Month 3) of the DBTP

    Severity of qualified migraine headache was measured by using 100 mm Visual Analogue Scale (VAS). Monthly average severity of migraine attack was defined as sum of the severity of each migraine episodes during the migraine attacks between two consecutive monthly IP doses divided by total number of observed migraine episodes during migraine attacks in that monthly interval. 100 mm VAS ranged from 0 to 100 mm, where 0 represents no pain (lowest severity of migraine) and 100 represents worst possible pain (highest severity of migraine). Negative change from baseline indicates an improvement in symptoms. LSM was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment with scheduled visit. Participants were used as a random effect. As pre-specified in the SAP, only results from adolescents are presented.

    Time frame: Baseline to Week 12

  5. Change From Baseline in Migraine-related Disability and Productivity as Measured by the Modified Pediatric Migraine Disability Assessment (PedMIDAS) to Week 9 Through Week 12 (Month 3) of the DBTP

    Modified PedMIDAS is a 6-item self-administered questionnaire that measures the disability in 2 settings: at school and at home. Modified PedMIDAS score is the sum of missed school days, days when activities at school or home were reduced by at least half due to headaches, and days when other family, social, leisure activities were reduced by at least half due to headaches. Modified PedMIDAS: 0-10: little/none;11-30: mild; 31-50: moderate; \>50; severe; Minimum value 0, maximum value 80, higher scores mean a worse outcome. Negative change from baseline indicates an improvement in symptoms. LSM was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment with scheduled visit. Participants were used as a random effect. As pre-specified in the SAP, only results from adolescents are presented.

    Time frame: Baseline to Week 12

07

Results

Posted Oct 28, 2026

Participant flow

A total of 284 participants were enrolled across 12 countries between Sep 2019 and Jan 2026. Participants entered a double-blind treatment phase (DBTP), initially planned for 24 weeks but reduced to 12 weeks following a protocol amendment. Participants in both treatment groups could enter a 40-week dose-level-blinded extension phase (DLBEP). AMG 334 recipients continued the same blinded dose, while placebo recipients were re-randomized 1:1 to AMG 334 dose level 1 or 2 in a double-blind manner.

DBTP Period
Participant flow — DBTP Period
MilestoneAdolescents - Placebo (DBTP)Adolescents - AMG 334 Dose Level 1 (DBTP)Adolescents - AMG 334 Dose Level 2 (DBTP)Children - Placebo (DBTP)Children - AMG 334 Dose Level 1 (DBTP)Children - AMG 334 Dose Level 2 (DBTP)Adolescent - AMG 334 Dose Level 1 (DLBEP)Adolescent - AMG 334 Dose Level 2 (DLBEP)Children - AMG 334 Dose Level 1 (DLBEP)Children - AMG 334 Dose Level 2 (DLBEP)
Started129656714540000
Completed124636413540000
Not completed5231000000
Withdrew: Participant request2131000000
Withdrew: Lost to follow-up1000000000
Withdrew: Reason missing2100000000
DLBEP Period
Participant flow — DLBEP Period
MilestoneAdolescents - Placebo (DBTP)Adolescents - AMG 334 Dose Level 1 (DBTP)Adolescents - AMG 334 Dose Level 2 (DBTP)Children - Placebo (DBTP)Children - AMG 334 Dose Level 1 (DBTP)Children - AMG 334 Dose Level 2 (DBTP)Adolescent - AMG 334 Dose Level 1 (DLBEP)Adolescent - AMG 334 Dose Level 2 (DLBEP)Children - AMG 334 Dose Level 1 (DLBEP)Children - AMG 334 Dose Level 2 (DLBEP)
Started0000001231231210
Completed0000009696119
Not completed000000272711
Withdrew: Participant request000000262511
Withdrew: Decision by sponsor0000000100
Withdrew: Lost to follow-up0000001100

Outcome measures

SecondaryChange From Baseline in Monthly Headache Days to Week 9 Through Week 12 (Month 3) of the DBTP

A headache day was defined as any calendar day in which the participant develops a qualified headache (onset, continuation, or recurrence of the headache). Monthly headache days were defined as the number of headache days between each monthly IP dose. Monthly headache days at baseline was the number of headache days in the 4-week baseline phase. LSM was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment with scheduled visit. Participants were used as a random effect. As pre-specified in the SAP, only results from adolescents are presented.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · days per month
Change From Baseline in Monthly Headache Days to Week 9 Through Week 12 (Month 3) of the DBTP
days per monthAdolescents - Placebo (DBTP)Adolescents - AMG 334 (DBTP)
Change From Baseline in Monthly Headache Days to Week 9 Through Week 12 (Month 3) of the DBTP-4.52 ± 0.59-5.02 ± 0.58
Statistical analysis
  • Adolescents - Placebo (DBTP) vs Adolescents - AMG 334 (DBTP) · Difference in lsm: -0.49 · 95% CI -2.10 to 1.12
SecondaryNumber of Participants With at Least 50% Reduction in MMD From Baseline to Week 9 Through Week 12 (Month 3) of the DBTP

A migraine day was defined as any calendar day in which the participant developed a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). MMD was defined as the number of migraine days between each monthly IP dose. MMD at baseline was the number of migraine days in the 4-week baseline phase. All participants included in the overall number of participants analyzed contributed to the post-baseline data for this endpoint. As pre-specified in the SAP, only results from adolescents are presented.

Time frame:
Baseline to Week 12
Reported as:
Number · participants
Number of Participants With at Least 50% Reduction in MMD From Baseline to Week 9 Through Week 12 (Month 3) of the DBTP
participantsAdolescents - Placebo (DBTP)Adolescents - AMG 334 (DBTP)
Number of Participants With at Least 50% Reduction in MMD From Baseline to Week 9 Through Week 12 (Month 3) of the DBTP3832
Statistical analysis
  • Adolescents - Placebo (DBTP) vs Adolescents - AMG 334 (DBTP) · Odds ratio (or): 0.76 · 95% CI 0.43 to 1.32
SecondaryChange From Baseline in MMD to the Average of the First 3 Months (Week 1 Through Week 12) of the DBTP

A migraine day was defined as any calendar day in which the participant developed a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). MMD was defined as the number of migraine days between each monthly IP dose. MMD at baseline was the number of migraine days in the 4-week baseline phase. LSM was calculated using a fixed effects analysis of covariance (ANCOVA) model, including terms for treatment group, baseline value as covariate, and stratification factors of region and prior preventive treatment failure. As pre-specified in the SAP, only results from adolescents are presented.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · days per month
Change From Baseline in MMD to the Average of the First 3 Months (Week 1 Through Week 12) of the DBTP
days per monthAdolescents - Placebo (DBTP)Adolescents - AMG 334 (DBTP)
Change From Baseline in MMD to the Average of the First 3 Months (Week 1 Through Week 12) of the DBTP-3.53 ± 0.51-3.48 ± 0.50
Statistical analysis
  • Adolescents - Placebo (DBTP) vs Adolescents - AMG 334 (DBTP) · Difference in lsm: 0.04 · 95% CI -1.33 to 1.42
SecondaryChange From Baseline in Monthly Average Severity of Migraine Attacks to Week 9 Through Week 12 (Month 3) of the DBTP

Severity of qualified migraine headache was measured by using 100 mm Visual Analogue Scale (VAS). Monthly average severity of migraine attack was defined as sum of the severity of each migraine episodes during the migraine attacks between two consecutive monthly IP doses divided by total number of observed migraine episodes during migraine attacks in that monthly interval. 100 mm VAS ranged from 0 to 100 mm, where 0 represents no pain (lowest severity of migraine) and 100 represents worst possible pain (highest severity of migraine). Negative change from baseline indicates an improvement in symptoms. LSM was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment with scheduled visit. Participants were used as a random effect. As pre-specified in the SAP, only results from adolescents are presented.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Monthly Average Severity of Migraine Attacks to Week 9 Through Week 12 (Month 3) of the DBTP
score on a scaleAdolescents - Placebo (DBTP)Adolescents - AMG 334 (DBTP)
Change From Baseline in Monthly Average Severity of Migraine Attacks to Week 9 Through Week 12 (Month 3) of the DBTP-1.67 ± 1.88-3.75 ± 1.84
Statistical analysis
  • Adolescents - Placebo (DBTP) vs Adolescents - AMG 334 (DBTP) · Difference in lsm: -2.08 · 95% CI -7.18 to 3.02
SecondaryChange From Baseline in Migraine-related Disability and Productivity as Measured by the Modified Pediatric Migraine Disability Assessment (PedMIDAS) to Week 9 Through Week 12 (Month 3) of the DBTP

Modified PedMIDAS is a 6-item self-administered questionnaire that measures the disability in 2 settings: at school and at home. Modified PedMIDAS score is the sum of missed school days, days when activities at school or home were reduced by at least half due to headaches, and days when other family, social, leisure activities were reduced by at least half due to headaches. Modified PedMIDAS: 0-10: little/none;11-30: mild; 31-50: moderate; \>50; severe; Minimum value 0, maximum value 80, higher scores mean a worse outcome. Negative change from baseline indicates an improvement in symptoms. LSM was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment with scheduled visit. Participants were used as a random effect. As pre-specified in the SAP, only results from adolescents are presented.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Migraine-related Disability and Productivity as Measured by the Modified Pediatric Migraine Disability Assessment (PedMIDAS) to Week 9 Through Week 12 (Month 3) of the DBTP
score on a scaleAdolescents - Placebo (DBTP)Adolescents - AMG 334 (DBTP)
Change From Baseline in Migraine-related Disability and Productivity as Measured by the Modified Pediatric Migraine Disability Assessment (PedMIDAS) to Week 9 Through Week 12 (Month 3) of the DBTP-7.53 ± 1.48-13.26 ± 1.47
Statistical analysis
  • Adolescents - Placebo (DBTP) vs Adolescents - AMG 334 (DBTP) · Difference in lsm: -5.74 · 95% CI -9.77 to -1.70
PrimaryChange From Baseline in MMD to Week 9 Through Week 12 (Month 3) of the DBTP

A migraine day was defined as any calendar day in which the participant developed a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). MMD was defined as the number of migraine days between each monthly IP dose. MMD at baseline was the number of migraine days in the 4-week baseline phase. The least squares mean (LSM) was calculated using a linear mixed effects repeated measures model including treatment group, baseline value as covariate, stratification factors of region and prior preventive treatment failure, scheduled visit, and interaction of treatment group with scheduled visit. Participants were used as a random effect. As pre-specified in the Statistical Analysis Plan (SAP), only results from adolescents are presented.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · days per month
Change From Baseline in MMD to Week 9 Through Week 12 (Month 3) of the DBTP
days per monthAdolescents - Placebo (DBTP)Adolescents - AMG 334 (DBTP)
Change From Baseline in MMD to Week 9 Through Week 12 (Month 3) of the DBTP-4.45 ± 0.63-4.53 ± 0.62
Statistical analysis
  • Adolescents - Placebo (DBTP) vs Adolescents - AMG 334 (DBTP) · Linear mixed effects repeated measures · p = 0.93 · Difference in lsm: -0.08 · 95% CI -1.80 to 1.65Model included treatment, baseline value, stratification factors, visit, and interaction of treatment with visit.

Adverse events

Collected over Up to Week 12 (for participants enrolled following the protocol amendment) or up to Week 24 (for participants enrolled under the original protocol), followed by 40-weeks DLBEP period, and then 12-weeks safety follow-up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adolescents - Placebo (DBTP)0/129 (0%)6/129 (4.7%)49/129 (38%)
Adolescents - AMG 334 (DBTP)0/132 (0%)4/132 (3%)53/132 (40.2%)
Children - Placebo (DBTP)0/14 (0%)1/14 (7.1%)8/14 (57.1%)
Children - AMG 334 (DBTP)0/9 (0%)0/9 (0%)4/9 (44.4%)
Adolescent - AMG 334 Dose Level 1 (DLBEP)0/123 (0%)5/123 (4.1%)66/123 (53.7%)
Adolescent - AMG 334 Dose Level 2 (DLBEP)0/123 (0%)12/123 (9.8%)66/123 (53.7%)
Children - AMG 334 Dose Level 1 (DLBEP)0/12 (0%)3/12 (25%)10/12 (83.3%)
Children - AMG 334 Dose Level 2 (DLBEP)0/10 (0%)0/10 (0%)8/10 (80%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventAdolescents - Placebo (DBTP)Adolescents - AMG 334 (DBTP)Children - Placebo (DBTP)Children - AMG 334 (DBTP)Adolescent - AMG 334 Dose Level 1 (DLBEP)Adolescent - AMG 334 Dose Level 2 (DLBEP)Children - AMG 334 Dose Level 1 (DLBEP)Children - AMG 334 Dose Level 2 (DLBEP)
Sinusitis bacterialInfections and infestations0/1290/1320/140/90/1230/1231/120/10
ObesityMetabolism and nutrition disorders0/1290/1320/140/90/1230/1231/120/10
AsthmaRespiratory, thoracic and mediastinal disorders0/1290/1320/140/90/1230/1231/120/10
Upper respiratory tract infectionInfections and infestations0/1290/1321/140/90/1230/1230/120/10
MigraineNervous system disorders0/1290/1321/140/90/1234/1230/120/10
Status migrainosusNervous system disorders2/1290/1320/140/90/1231/1230/120/10
Helicobacter gastritisInfections and infestations0/1291/1320/140/91/1230/1230/120/10
AppendicolithGastrointestinal disorders0/1290/1320/140/90/1231/1230/120/10
Anaphylactic reactionImmune system disorders0/1290/1320/140/91/1230/1230/120/10
Campylobacter colitisInfections and infestations0/1290/1320/140/90/1231/1230/120/10
Most frequent other events
Showing 10 of 51
Most frequent other events
EventAdolescents - Placebo (DBTP)Adolescents - AMG 334 (DBTP)Children - Placebo (DBTP)Children - AMG 334 (DBTP)Adolescent - AMG 334 Dose Level 1 (DLBEP)Adolescent - AMG 334 Dose Level 2 (DLBEP)Children - AMG 334 Dose Level 1 (DLBEP)Children - AMG 334 Dose Level 2 (DLBEP)
NasopharyngitisInfections and infestations12/12913/1322/140/917/12321/1233/121/10
Upper respiratory tract infectionInfections and infestations3/1298/1320/141/911/12314/1232/121/10
InfluenzaInfections and infestations2/1293/1321/140/96/1236/1232/121/10
AsthmaRespiratory, thoracic and mediastinal disorders0/1291/1320/140/91/1230/1232/120/10
COVID-19Infections and infestations9/1299/1321/140/915/12314/1230/121/10
Injection site reactionGeneral disorders0/1292/1320/141/91/1231/1230/120/10
HordeolumInfections and infestations0/1291/1320/141/90/1230/1230/120/10
HeadacheNervous system disorders0/1294/1320/141/94/1232/1231/120/10
Abdominal pain upperGastrointestinal disorders3/1292/1321/140/91/1235/1230/121/10
BronchitisInfections and infestations1/1290/1321/140/90/1231/1230/121/10

Baseline characteristics

Full analysis set: all participants who were randomized in the trial.

Age, Continuous
Age, Continuous(years)Adolescents - Placebo (DBTP)Adolescents - AMG 334 (DBTP)Children - Placebo (DBTP)Children - AMG 334 (DBTP)Total
Mean15.36 ± 1.4015.12 ± 1.589.79 ± 1.378.78 ± 1.6414.77 ± 2.19
Sex: Female, Male
Sex: Female, Male(Participants)Adolescents - Placebo (DBTP)Adolescents - AMG 334 (DBTP)Children - Placebo (DBTP)Children - AMG 334 (DBTP)Total
Female10310684221
Male26266563
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Adolescents - Placebo (DBTP)Adolescents - AMG 334 (DBTP)Children - Placebo (DBTP)Children - AMG 334 (DBTP)Total
Hispanic or Latino950014
Not Hispanic or Latino120127149270
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Adolescents - Placebo (DBTP)Adolescents - AMG 334 (DBTP)Children - Placebo (DBTP)Children - AMG 334 (DBTP)Total
American Indian or Alaska Native00000
Asian22181041
Native Hawaiian or Other Pacific Islander00000
Black or African American21205
White98106119224
More than one race24006
Unknown or Not Reported53008
Monthly Migraine Days (MMD) During Baseline Phase
Monthly Migraine Days (MMD) During Baseline Phase(days per month)Adolescents - Placebo (DBTP)Adolescents - AMG 334 (DBTP)Children - Placebo (DBTP)Children - AMG 334 (DBTP)Total
Mean19.90 ± 5.3019.83 ± 5.8819.62 ± 5.0618.86 ± 5.1419.82 ± 5.54
08

Study locations

101 sites
  • Paradigm Clinical Research Center Inc
    San Diego, California 92108, United States
  • Childrens Hospital Colorado
    Aurora, Colorado 80045, United States
  • Colorado Springs Neurological Associates
    Colorado Springs, Colorado 80907, United States
  • New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • Childrens National Health System
    Washington D.C., District of Columbia 20010, United States
  • TrueBlue Clinical Research
    Brandon, Florida 33511, United States
  • Northwest Florida Clinical Research Group Limited Liability Company
    Gulf Breeze, Florida 32561, United States
  • Nicklaus Childrens Hospital
    Miami, Florida 33155, United States
  • Pediatric Epilepsy and Neurology Specialists
    Tampa, Florida 33609, United States
  • Premiere Research Institute
    West Palm Beach, Florida 33407, United States
  • Rare Disease Research Center Pediatrics
    Atlanta, Georgia 30329, United States
  • CenExel iResearch, LLC
    Savannah, Georgia 31405, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Chicago Headache Center and Research Institute
    Chicago, Illinois 60657, United States
  • Josephson Wallack Munshower Neurology
    Indianapolis, Indiana 46256, United States
  • University of Maryland, Baltimore
    Baltimore, Maryland 21201, United States
  • New England Regional Headache Center Inc
    Worcester, Massachusetts 14226, United States
  • Michigan Head Pain and Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Clinical Research Institute Inc
    Plymouth, Minnesota 55441, United States
  • Childrens Mercy Hospital and Clinics
    Kansas City, Missouri 64108, United States
  • Mercy Research
    St Louis, Missouri 63141, United States
  • Meridian Clinical Research LLC
    Hastings, Nebraska 68901, United States
  • Dent Neurosciences Research Center
    Amherst, New York 14226, United States
  • Modern Migraine MD
    New York, New York 10001, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
  • Cincinnati Childrens Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Nationwide Childrens Hospital
    Columbus, Ohio 43205, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Childrens Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Preferred Primary Care Physicians, Inc
    Pittsburgh, Pennsylvania 15236, United States
  • Palmetto Gastroenterology Clinical Research, LLC
    Summerville, South Carolina 29486, United States
  • Child Neurology Consultants of Austin
    Austin, Texas 78757, United States
  • Helios Clinical Research Inc
    Burleson, Texas 76028, United States
  • Stryde Consulting LLC
    Frisco, Texas 75033, United States
  • Childrens Specialty Group
    Norfolk, Virginia 23507, United States
  • Vaught Neurological Services
    Crab Orchard, West Virginia 25827, United States
  • Marshfield Clinic
    Marshfield, Wisconsin 54449, United States
  • Universitair Ziekenhuis Brussel
    Brussels, 1090, Belgium
  • Algemeen Ziekenhuis Sint-Maarten
    Mechelen, 2800, Belgium
  • Docteur Simona Sava
    Saint-Nicolas, 4420, Belgium
  • Stollery Childrens Hospital
    Edmonton, Alberta T6G 1C9, Canada
  • London Health Sciences Centre
    London, Ontario N6A 4G5, Canada
  • Childrens Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • The Hospital For Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • Fundacion Centro de Investigacion Clinica
    Medellín, Antioquia 050021, Colombia
  • Cafam
    Bogota, Cundinamarca 111211, Colombia
  • Fundacion Cardiovascular de Colombia
    Bucaramanga, Santander Department 681017, Colombia
  • Terveystalo Pulssi
    Turku, 20100, Finland
  • Charite - Universitaetsmedizin Berlin, Campus Virchow
    Berlin, 13353, Germany
  • Universitaetsklinikum Essen
    Essen, 45147, Germany
  • Schmerzklinik Kiel
    Kiel, 24149, Germany
  • Arzneimittelforschung Leipzig GmbH
    Leipzig, 04107, Germany
  • Dr Kenessey Albert Korhaz - Rendelointezet
    Balassagyarmat, 2660, Hungary
  • Dr Altmann Anna egyeni vallalkozo
    Budapest, 1026, Hungary
  • High Tech Medical Kft
    Budapest, 1027, Hungary
  • Semmelweis Egyetem
    Budapest, 1094, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz
    Miskolc, 3526, Hungary
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
    Milan, 20133, Italy
  • Azienda di Rilievo Nazionale e Alta Specializzazione Civico Di Cristina Benfratelli
    Palermo, 90134, Italy
  • Fondazione Istituto Neurologico Nazionale C Mondino IRCCS
    Pavia, 27100, Italy
  • IRCCS Ospedale Pediatrico Bambino Gesu
    Roma, 00165, Italy
  • Josai Kids Clinic
    Nagoya, Aichi-ken 451-0031, Japan
  • Medical Corporation Seikokai Takanoko Hospital
    Matsuyama, Ehime 790-0925, Japan
  • Hiroshima City Hiroshima Citizens Hospital
    Hiroshima, Hiroshima 730-8518, Japan
  • Kitami Clinic
    Sapporo, Hokkaido 060-0004, Japan
  • Konan Medical Center
    Kobe, Hyōgo 658-0064, Japan
  • Kumamoto City Hospital
    Kumamoto, Kumamoto 862-8505, Japan
  • Tatsuoka Neurology Clinic
    Kyoto, Kyoto 600-8811, Japan
  • Japanese Red Cross Kyoto Daiichi Hospital
    Kyoto, Kyoto 605-0981, Japan
  • Sendai Headache and Neurology Clinic
    Sendai, Miyagi 982-0014, Japan
  • Tominaga Hospital
    Osaka, Osaka 556-0017, Japan
  • Saitama Neuropsychiatric Institute
    Saitama-shi, Saitama 338-8577, Japan
  • Tokyo Headache Clinic
    Shibuya-ku, Tokyo 151-0051, Japan
  • Tokyo Medical University Hospital
    Shinjuku-ku, Tokyo 160-0023, Japan
  • Keio University Hospital
    Shinjuku-ku, Tokyo 160-8582, Japan
  • Nagamitsu Clinic
    Hofu-shi, Yamaguchi 747-0802, Japan
  • Nagaseki Headache Clinic
    Kai-shi, Yamanashi 400-0124, Japan
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • Instytut Centrum Zdrowia Matki Polki
    Lodz, 93-338, Poland
  • Centrum Medyczne Luxmed Spzoo
    Lublin, 20-109, Poland
  • Centrum Medyczne Hope Clinic Sebastian Szklener
    Lublin, 20-701, Poland
  • Uniwersytecki Szpital Kliniczny w Poznaniu
    Poznan, 60-355, Poland
  • Clinical Research Center Spzoo Medic-R Spolka Komandytowa
    Poznan, 61-731, Poland
  • Dr Sekowska Leczenie Bolu
    Warsaw, 01-018, Poland
  • Next Stage Spzoo
    Warsaw, 02-121, Poland
  • Migre Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak
    Wroclaw, 52-210, Poland
  • Puerto Rico Health and Wellness Institute
    Dorado, 00646, Puerto Rico
  • FSBI Russian Children Clinical Hospital of the MoH RF
    Moscow, 119571, Russia
  • LLC clinic Chaika
    Moscow, 125047, Russia
  • LLC Sibneyromed
    Novosibirsk, 630004, Russia
  • LLC Medical Technologies
    Saint Petersburg, 191025, Russia
  • Noahs Ark Childrens Hospital for Wales
    Cardiff, CF14 4XW, United Kingdom
  • Royal Hospital for Children
    Glasgow, G51 4TF, United Kingdom
  • 4 Medical Clinical Solutions London
    Ilford, IG1 4HP, United Kingdom
  • Alder Hey Childrens Hospital
    Liverpool, L12 2AP, United Kingdom
  • Evelina Childrens Hospital
    London, SE1 7EU, United Kingdom
  • Great Ormond Street Hospital for Children
    London, WC1N 3JH, United Kingdom
  • 4 Medical Clinical Solutions Manchester
    Manchester, M27 8FF, United Kingdom

Showing the first 100 of 101 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Jan 2025, 64 months.

Results were first posted in Oct 2026, 1 year 9 months after primary completion. A results delay was requested in Oct 2025.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 64 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2019
First posted
Feb 6, 2019
StartActual
Sep 5, 2019
Primary completionActual
Jan 8, 2025
CompletionActual
Jan 7, 2026
Results delay requested
Oct 3, 2025
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Change from baseline in MMDsNow Change From Baseline in MMD to Week 9 Through Week 12 (Month 3) of the DBTPTime frame: Baseline through week 12 of DBTP → Baseline to Week 12
Oct 28, 2026
Documents
Secondary outcomes
3 edited, 2 added, 10 removed
What changed in the outcomes
  • EditedProportionNumber of participants withParticipants With at leastLeast 50% reductionReduction in MMDs from baselineMMD From Baseline to Week 9 Through Week 12 (Month 3) of the DBTPTime frame: Baseline through week 12 of the DBTP → Baseline to Week 12
  • EditedChange From Baseline in MMDs from baselineMMD to the averageAverage of the firstFirst 3 monthsMonths (Week 1 Through Week 12) of the DBTPTime frame: Baseline through week 12 of the DBTP → Baseline to Week 12
  • EditedChange from baselineFrom Baseline in migraineMigraine-related disabilityDisability and productivityProductivity as assessedMeasured by the Modified Pediatric Migraine Disability Assessment (PedMIDAS) to Week 9 Through Week 12 (Month 3) of the DBTPTime frame: Baseline through week 12 of the DBTP → Baseline to Week 12
  • AddedChange From Baseline in Monthly Headache Days to Week 9 Through Week 12 (Month 3) of the DBTPTime frame: Baseline to Week 12
  • AddedChange From Baseline in Monthly Average Severity of Migraine Attacks to Week 9 Through Week 12 (Month 3) of the DBTPTime frame: Baseline to Week 12
  • RemovedChange in monthly headache days from baselineTime frame: Baseline through week 12 of the DBTP
  • RemovedChange in monthly average severity of migraine attacks from baseline (measured with a visual analogue scale)Time frame: Baseline through week 12 of the double blind treatment phase
  • RemovedNumber of participants experiencing Treatment-emergent Adverse Events (TEAE)Time frame: Up to Week 83
  • RemovedNumber of participants expressing C Terminal Telopeptide of Type 1 Collagen (CTX) MarkersTime frame: Up to week 83
  • RemovedNumber of participants expressing Procollagen Type 1 N Propeptide (P1NP) MarkersTime frame: Up to week 83
  • RemovedNumber of participants expressing Anti-erenumab antibodiesTime frame: Up to week 83
  • RemovedChange in growth and development rate as assessed by physical measuraments based on age-adjusted Z-scores for height and weightTime frame: Up to week 83
  • RemovedNumber of participants experiencing treatment-emergent suicidal ideation and behavior as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS).Time frame: Up to week 83
  • RemovedGroup 1 only: Number of participants experiencing injection site pain as assessed by Face Pain Scale-revised (FPS-R)Time frame: Day 1 and week 20
  • RemovedGroup 2 only: Number of participants experiencing injection site pain as assessed by FPS-RTime frame: Day 1 and week 8
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Change from baseline in MMDsNow Change From Baseline in MMD to Week 9 Through Week 12 (Month 3) of the DBTPTime frame: Baseline through week 12 of DBTP → Baseline to Week 12
    Secondary outcomes 3 edited, 2 added, 10 removed
    What changed in the outcomes
    • EditedProportionNumber of participants withParticipants With at leastLeast 50% reductionReduction in MMDs from baselineMMD From Baseline to Week 9 Through Week 12 (Month 3) of the DBTPTime frame: Baseline through week 12 of the DBTP → Baseline to Week 12
    • EditedChange From Baseline in MMDs from baselineMMD to the averageAverage of the firstFirst 3 monthsMonths (Week 1 Through Week 12) of the DBTPTime frame: Baseline through week 12 of the DBTP → Baseline to Week 12
    • EditedChange from baselineFrom Baseline in migraineMigraine-related disabilityDisability and productivityProductivity as assessedMeasured by the Modified Pediatric Migraine Disability Assessment (PedMIDAS) to Week 9 Through Week 12 (Month 3) of the DBTPTime frame: Baseline through week 12 of the DBTP → Baseline to Week 12
    • AddedChange From Baseline in Monthly Headache Days to Week 9 Through Week 12 (Month 3) of the DBTPTime frame: Baseline to Week 12
    • AddedChange From Baseline in Monthly Average Severity of Migraine Attacks to Week 9 Through Week 12 (Month 3) of the DBTPTime frame: Baseline to Week 12
    • RemovedChange in monthly headache days from baselineTime frame: Baseline through week 12 of the DBTP
    • RemovedChange in monthly average severity of migraine attacks from baseline (measured with a visual analogue scale)Time frame: Baseline through week 12 of the double blind treatment phase
    • RemovedNumber of participants experiencing Treatment-emergent Adverse Events (TEAE)Time frame: Up to Week 83
    • RemovedNumber of participants expressing C Terminal Telopeptide of Type 1 Collagen (CTX) MarkersTime frame: Up to week 83
    • RemovedNumber of participants expressing Procollagen Type 1 N Propeptide (P1NP) MarkersTime frame: Up to week 83
    • RemovedNumber of participants expressing Anti-erenumab antibodiesTime frame: Up to week 83
    • RemovedChange in growth and development rate as assessed by physical measuraments based on age-adjusted Z-scores for height and weightTime frame: Up to week 83
    • RemovedNumber of participants experiencing treatment-emergent suicidal ideation and behavior as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS).Time frame: Up to week 83
    • RemovedGroup 1 only: Number of participants experiencing injection site pain as assessed by Face Pain Scale-revised (FPS-R)Time frame: Day 1 and week 20
    • RemovedGroup 2 only: Number of participants experiencing injection site pain as assessed by FPS-RTime frame: Day 1 and week 8
    + 4 other changes: index terms, identifiers, verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03832998
Lead sponsor
Amgen
Collaborators
Novartis
Responsible party
Sponsor
First posted
Feb 6, 2019
Start date
Sep 5, 2019
Primary completion
Jan 8, 2025
Completion
Jan 7, 2026
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Erenumab

Start the discussion